Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1984 Oct;37(10):1153–1156. doi: 10.1136/jcp.37.10.1153

Immunological comparison between human and rat plasminogen activators in blood and the vessel wall.

A Kjaeldgaard, B Larsson, B Astedt
PMCID: PMC498958  PMID: 6541663

Abstract

To evaluate the rat as an experimental model for plasminogen activator research, the ability of antibodies specific for human tissue type plasminogen activator and urokinase to suppress the plasminogen activator activity in whole plasma and in the vessel wall was studied in both rat and man. Plasminogen activator activity in plasma was assayed on fibrin plates containing plasminogen. Plasminogen activator in the vessel wall was shown by the fibrin side technique. Antibodies against human tissue type melanoma cell activator and urokinase were raised in goats and mixed into the fibrin film or the fibrin plates. In both species antibodies to melanoma cell activator were able to suppress the plasminogen activator activity completely in plasma and in the vessel wall. Anti-urokinase, however, had no suppressing effect. In rat plasma the inhibitory effect on the fibrinolytic activity was seen only with high concentrations of antibodies against melanoma cell activator, which suggests that rat plasminogen activator in plasma and vessel walls is similar to, but not identical with, human tissue type plasminogen activator.

Full text

PDF
1153

Images in this article

1155Image
on p.1155

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bykowska K., Rijken D. C., Collen D. Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture. Thromb Haemost. 1981 Oct;46(3):642–644. [PubMed] [Google Scholar]
  2. Emeis J. J. Perfused rat hindlegs. A model to study plasminogen activator release. Thromb Res. 1983 May 1;30(3):195–203. doi: 10.1016/0049-3848(83)90072-5. [DOI] [PubMed] [Google Scholar]
  3. Haverkate F., Traas D. W. Dose-response curves in the fibrin plate assay. Fibrinolytic acitivity of proteases. Thromb Diath Haemorrh. 1974 Dec 31;32(2-3):356–365. [PubMed] [Google Scholar]
  4. Holmberg L., Bladh B., Astedt B. Purification of urokinase by affinity chromatography. Biochim Biophys Acta. 1976 Aug 12;445(1):215–222. doi: 10.1016/0005-2744(76)90174-1. [DOI] [PubMed] [Google Scholar]
  5. Holmberg L., Kristoffersson A. C., Lecander I., Wallén P., Astedt B. Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase. Scand J Clin Lab Invest. 1982 Jun;42(4):347–354. [PubMed] [Google Scholar]
  6. Holmberg L., Nilsson I. M., Wallén P., Astedt B. Studies of the blood plasminogen activator induced by 1-desamino-8-D-arginine vasopressin with observations in von Willebrand's disease. Proc Soc Exp Biol Med. 1982 Jun;170(2):126–132. doi: 10.3181/00379727-170-41407. [DOI] [PubMed] [Google Scholar]
  7. Korninger C., Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost. 1981 Aug 28;46(2):561–565. [PubMed] [Google Scholar]
  8. Ljungnér H., Holmberg L., Kjeldgaard A., Nilsson I. M., Astedt B. Immunological characterisation of plasminogen activators in the human vessel wall. J Clin Pathol. 1983 Sep;36(9):1046–1049. doi: 10.1136/jcp.36.9.1046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Murano G. The "Hageman" connection: interrelationships of blood coagulation, fibrino(geno)lysis, kinin generation, and complement activation. Am J Hematol. 1978;4(4):409–417. doi: 10.1002/ajh.2830040412. [DOI] [PubMed] [Google Scholar]
  10. NILSSON I. M., OLOW B. Determination of fibrinogen and fibrinogenolytic activity. Thromb Diath Haemorrh. 1962 Nov 15;8:297–310. [PubMed] [Google Scholar]
  11. Pandolfi M., Robertson B., Isacson S., Nilsson I. M. Fibrinolytic activity of human veins in arms and legs. Thromb Diath Haemorrh. 1968 Nov 15;20(1):247–256. [PubMed] [Google Scholar]
  12. Pennica D., Holmes W. E., Kohr W. J., Harkins R. N., Vehar G. A., Ward C. A., Bennett W. F., Yelverton E., Seeburg P. H., Heyneker H. L. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature. 1983 Jan 20;301(5897):214–221. doi: 10.1038/301214a0. [DOI] [PubMed] [Google Scholar]
  13. Rijken D. C., Wijngaards G., Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res. 1980 Jun 15;18(6):815–830. doi: 10.1016/0049-3848(80)90204-2. [DOI] [PubMed] [Google Scholar]
  14. Roblin R., Young P. L. Dexamethasone regulation of plasminogen activator in embryonic and tumor-derived human cells. Cancer Res. 1980 Aug;40(8 Pt 1):2706–2713. [PubMed] [Google Scholar]
  15. Shakespeare M., Wolf P. The demonstration of urokinase antigen in whole blood. Thromb Res. 1979;14(6):825–835. doi: 10.1016/0049-3848(79)90002-1. [DOI] [PubMed] [Google Scholar]
  16. Tissot J. D., Schneider P., Hauert J., Ruegg M., Kruithof E. K., Bachmann F. Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest. 1982 Dec;70(6):1320–1323. doi: 10.1172/JCI110733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Vetterlein D., Young P. L., Bell T. E., Roblin R. Immunological characterization of multiple weight forms of human cell plasminogen activators. J Biol Chem. 1979 Feb 10;254(3):575–578. [PubMed] [Google Scholar]
  18. Wijngaards G., Kluft C., Groeneveld E. Demonstration of urokinase-related fibrinolytic activity in human plasma. Br J Haematol. 1982 May;51(1):165–169. doi: 10.1111/j.1365-2141.1982.tb07300.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES